{"name":"BeOne Medicines","slug":"beone-medicines","ticker":"","exchange":"","domain":"beonemedicines.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"BG-C9074","genericName":"BG-C9074","slug":"bg-c9074","indication":"Other","status":"phase_1"},{"name":"BG-75098","genericName":"BG-75098","slug":"bg-75098","indication":"Other","status":"phase_1"},{"name":"BG-A3004","genericName":"BG-A3004","slug":"bg-a3004","indication":"Other","status":"phase_1"},{"name":"BG-C0902","genericName":"BG-C0902","slug":"bg-c0902","indication":"Other","status":"phase_1"},{"name":"BG-C477","genericName":"BG-C477","slug":"bg-c477","indication":"Other","status":"phase_1"},{"name":"BGB-43395","genericName":"BGB-43395","slug":"bgb-43395","indication":"Other","status":"phase_1"},{"name":"BGB-B2033","genericName":"BGB-B2033","slug":"bgb-b2033","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Subcutaneous Tislelizumab","genericName":"Subcutaneous Tislelizumab","slug":"subcutaneous-tislelizumab","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BGB-16673","genericName":"BGB-16673","slug":"bgb-16673","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"Intravenous Tislelizumab","genericName":"Intravenous Tislelizumab","slug":"intravenous-tislelizumab","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"BG-C9074","genericName":"BG-C9074","slug":"bg-c9074","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BG-75098","genericName":"BG-75098","slug":"bg-75098","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BG-A3004","genericName":"BG-A3004","slug":"bg-a3004","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BG-C0902","genericName":"BG-C0902","slug":"bg-c0902","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BG-C477","genericName":"BG-C477","slug":"bg-c477","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BGB-43395","genericName":"BGB-43395","slug":"bgb-43395","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subcutaneous Tislelizumab","genericName":"Subcutaneous Tislelizumab","slug":"subcutaneous-tislelizumab","phase":"phase_3","mechanism":"Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Hepatocellular carcinoma","Gastric or gastroesophageal junction cancer","Esophageal squamous cell carcinoma"],"catalyst":""},{"name":"BGB-16673","genericName":"BGB-16673","slug":"bgb-16673","phase":"phase_3","mechanism":"BGB-16673 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"BGB-B2033","genericName":"BGB-B2033","slug":"bgb-b2033","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Intravenous Tislelizumab","genericName":"Intravenous Tislelizumab","slug":"intravenous-tislelizumab","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that blocks PD-1 on T cells to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Hepatocellular carcinoma","Gastric or gastroesophageal junction cancer","Esophageal squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxObUhtSWk1emNCVzRuRkhTTWxnRk93S0RQNVlpM19wcnVkY2tCSWNxUUhsQkJteFFOcVZYUk1rRGg3SHRYNVBTWVUzQXRrcU9SVnFXOVVpak54WVZiN04zT0hSRHhVclJGN2dRdi1WN3I5TXZDekVuZWxXYkFTTHJ5M2NkSXk0M3paeVkxc3dlcnFqdlNJ?oc=5","date":"2026-03-10","type":"pipeline","source":"The Pharma Letter","summary":"BeOne’s tislelizumab now available in Ireland - The Pharma Letter","headline":"BeOne’s tislelizumab now available in Ireland","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"pipeline","source":"simplywall.st","summary":"BeOne Medicines Pharma Alliances Contrast With High P/E And Valuation Upside - simplywall.st","headline":"BeOne Medicines Pharma Alliances Contrast With High P/E And Valuation Upside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOcTBodGtWMVVTZGFwZVhzUzFULWx1alF4UVJ1ZDhXRklTVTl1YldlZW5LV1QtSkVta3FlSzVJNktVS1psV3VPT3pEVk1HcVYwbmtid0xnZGNfOVo1RVpLaHNFYlVSNFpzaG52NlJ1bjVfYWJSOWlFV0dKcngzSll0SjVrUnBmM0RGMThNZllXSjM0MnV6M0pzYThvWm5VNEo0?oc=5","date":"2026-02-28","type":"pipeline","source":"seekingalpha.com","summary":"BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026 (NASDAQ:ONC) - seekingalpha.com","headline":"BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026 (NASDAQ:ONC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPQ2dSSnJmcV9SV3JtZFRkelJLOXhNa2NTeW10OVhzbDM2ZHhObThxdV81TURlaG1OSkVKQVdQQlBaRzBIYmxCVDRsTlF0dkpXTlFBNVg4R19RVnIxV0xjS2hhdUpaVWlycjRqY0k3VFVxTWg5TVR3RnZTRzJSbHprb3d5ZkJBQWxPS2RrdEhIZw?oc=5","date":"2026-02-26","type":"earnings","source":"Yahoo Finance","summary":"BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership - Yahoo Finance","headline":"BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOSjRpR2FlcTdabGZydXJ2RlVFWWR1Tjdaa0dUTllUbnVuVTdkYVRVYVV2dURLeHE0Mzdvb0w5cDZOQUJzUjRsSzhZQzEzdmlQNzJRSkRURFg1ZWRUREd3VGJTNmQzOEtVOWxYSW15VXUyOURfaEhWZ3pWRkI5UmJWM3JVNzhURlpHNEdPZF91SmFFblhZNEVlbmk3ZU5vcW1DRUQtX1ZKQUJXWElWcGtSODdHWTFjbkNqOTRnYXBWbE1zRjg1N0ZJWFZReXVKX0piRERPRnMwQXpFT2MwakpLVXZXVlBmQQ?oc=5","date":"2026-02-11","type":"earnings","source":"businesswire.com","summary":"BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 - businesswire.com","headline":"BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQUXJad2h5Ynl1eE1jTlBaNDlzLWtKZEo3Tm5KSkJPTW15akxBTHF2a19PdFdKZ3U1a1EtRENqMm9FakxsY09GNjFNQ3lpVUV2V09wdVhWVDJIeDRVaVVxcTZ2RWFJN05qVFlEay1tNlhQal9YSEVGWkVSQzRzSE5qQ2RMcEFQMDdCRGZ5RUQzZw?oc=5","date":"2026-01-12","type":"regulatory","source":"Medical Marketing and Media","summary":"FDA knocks BeOne Medicines for its use of Teams backgrounds in Untitled Letter - Medical Marketing and Media","headline":"FDA knocks BeOne Medicines for its use of Teams backgrounds in Untitled Letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPd3FPcHAzUThyZ3hmcEpFT0xtd29HQlZpellyeERYa2k4SVhfVXlscWNzRlBMZUpXQ3FLeldwX2lMRnRDWThScEZUOGVaaGVoWFVjTkJkaE52VHp1bEJNb0s0dEU5LV9vY0dVOXdzYmVKUUQybElZM1pVWjVuR3NRV1ZZbXVsVUpFOTNacEJlckFrM2tiVXlCMg?oc=5","date":"2025-12-07","type":"pipeline","source":"statnews.com","summary":"Hengrui, BeOne top new analysis of Chinese drug development | STAT - statnews.com","headline":"Hengrui, BeOne top new analysis of Chinese drug development | STAT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNbE5WM3FRdG5RVmlfbXk5WFBhU2tYOU9XNzBtVXFLdzFvSDQxdm5ieGJxNmRCckZnU1FKTE5laEg2NDZCVDlNMjh3NWVPUk1jd1I5QVZPOFI2bm0xblVtOWVzSmdiVmJiTGpjVGFiaU05VlZoY0RjYm13TnpCY1ZabXg2OW5fOGJQOXBaeklMZjRrQTlXYzVhVmU5cG1yVk44YTBFcFpsUWJCdlM1cGlLcGU0NDZyODY0TjlnVDdUeGdxaUF2NkJtYzBB?oc=5","date":"2025-11-21","type":"earnings","source":"Investor's Business Daily","summary":"This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452% - Investor's Business Daily","headline":"This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452% - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQcDIwV0pOQUVLaDdWTG9FdS1TYzlzQmpsZ2FRY2I2aUdhdWdyUW1ZRHRDUXNqQkdKTXlDNGlkMVpEeWFSSmVfc2hZaWk0WlM0QkFSclhJd2NJb3RobVhZanpJV211OWs1RjNVVW9VdE5LVDFXOVVUSlZETGtvUGpJNmQxa0I?oc=5","date":"2025-09-10","type":"pipeline","source":"Pharma Voice","summary":"Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city. - Pharma Voice","headline":"Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQZDhINlpPZWxWTHNKOUozRURpd0hZYmRLdTdCTTBmZ3p1VWxPbkpuVktnWVhIS2lXTGlqZEZodTU2UW82M0llYlV5bmM4Q1pKUVFpdWo4ZWt5V1VrbjlzZ3gwenIzb2ZnYmVYMVR2eUFHbWE2R1l4THQxb214VWthc3RyVjZDVGhxTDktOA?oc=5","date":"2025-08-25","type":"deal","source":"BioPharma Dive","summary":"Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales - BioPharma Dive","headline":"Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQTVBHbGs3TEVydmpHbllpQ0xIdTRlZFVFSzFqeHlWM1l4SkdtTi1TZFhVWk5JVVNwc3RpQ2lCVzRCXzE1Y00ydHBzYUhaX202TzktaVg2WXpwYjlta3VRQkFPWTg3cmxQUHJwdnU3MVR2QTdESDFabHZ4cVZBYW1HRmRCZ05MWDlGRUJWbDhCMmI1NnhsbGx0OUo4b3pOTkpEVnBQLWNVaVM0NVJYcFc0UHNfaXgtMllfTmI4QVFDZ0N0VFEwU0dZMw?oc=5","date":"2025-08-25","type":"pipeline","source":"Pharmaceutical Executive","summary":"BeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for Imdelltra - Pharmaceutical Executive","headline":"BeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for Imdelltra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPcUNaVWdObzFEam5IYThoWDRWRGdQeklUejVaSUo1dlpQWUpkT213Z3U0bmVBd3J5WDVYMjYtQ2V6T0FoemRwb2hhVnRvODZOa3dhTnk3LXJyWWJnUFZ6aFBtNmRBYlRWVjJ5a2wzYV9jajJRbjduQXNab2NiajNJLW1WdDN3YkducV9KeW12ZW5pVV9wclJLX2x0aFlRbkRuLVpqOUpFd242b2h0SVRmNw?oc=5","date":"2025-08-06","type":"pipeline","source":"Fierce Pharma","summary":"BeOne, now a Swiss company, widens Brukinsa's BTK lead over AstraZeneca's Calquence - Fierce Pharma","headline":"BeOne, now a Swiss company, widens Brukinsa's BTK lead over AstraZeneca's Calquence","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_1":7,"phase_3":3},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}